Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Furthering cell therapy ambition across oncology and autoimmune diseases
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Subscribe To Our Newsletter & Stay Updated
